✦ LIBER ✦

710 DOSE FINDING AND EFFICACY PHASE 2 STUDY OF INECALCITOL, A NEW VDR AGONIST, IN COMBINATION WITH DOCETAXEL-PREDNISONE REGIMEN FOR CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS (PTS)

✍ Scribed by Medioni, Jacques; Deplanque, Gael; Maurina, Tristan; Ferrero, Jean-Marc; Rodier, Jean-Michel; Raymond, Eric; Ayllon, Jorge; Renaux, Stephanie; Dufour-Lamartinie, Jean-Francois; Oudard, Stephane

Book ID: 123324900
Publisher: Lippincott Williams and Wilkins
Year: 2011
Tongue: English
Weight: 150 KB
Volume: 185
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2011.02.1678

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

430 Dose finding of inecalcitol, a new V

430 Dose finding of inecalcitol, a new VDR agonist, in combination with docetaxel–prednisone regimen for castrate-resistant prostate cancer (HRPC) patients (pts)

✍ J. Medioni; G. Deplanque; J.M. Ferrero; T. Maurina; J.M. Rodier; E. Raymond; G. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Phase I Safety and Pharmacodynamic of In

Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients

✍ Medioni, J.; Deplanque, G.; Ferrero, J.-M.; Maurina, T.; Rodier, J.-M. P.; Raymo 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 360 KB

7024 Phase Ib dose-finding trial of intr

7024 Phase Ib dose-finding trial of intravenous (i.v.) panobinostat (PAN) with docetaxel (DOC) and prednisone (PRED) in patients (pts) with castration resistant prostate cancer (CRPC)

✍ Vaishampayan, U.; Rathkopf, D.; Chi, K.N.; Hotte, S.; Vogelzang, N.; Alumkal, J. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 66 KB